

DermaSpan™ Acellular Dermal Matrix

Product Brochure

An acellular matrix derived
from allograft human skin.




ZIMMER BIOMET
Your progress. Our promise.®

Sterilization has its advantages

Through a proprietary process DermaSpan Acellular Dermal Matrix is supplied sterile (SAL-10⁻⁶). Histology studies have shown that Precision Dose Sterilization allows the graft to be sterilized while maintaining tissue integrity.¹


Histology Studies¹

These histology studies show no changes to the matrix, post sterilization:



Transmission Electron Micrographs (TEMs)¹

TEMs presented the same results. There is a similar collagen structure between normal dermis and dermis treated with the gamma precision sterilization process. Ultimately, DermaSpan Acellular Dermal Matrix is preserved through processing.



Sterilization has its advantages

DermaSpan Acellular Dermal Matrix is carefully processed to offer biocompatibility as well as biomechanical strength. DermaSpan ACD can be used in various practices, including plastics and general surgery, for the repair or replacement of damaged or inadequate integumental tissue (wound coverage). DermaSpan ACD can also be for supplemental support, protection, reinforcement or covering of tendon. DermaSpan Acellular Dermal Matrix has the added advantage of being supplied sterile... unlike many other dermal allograft products.



Wound Coverage




Tendon Coverage

Feature	Benefit
Acellular dermal matrix	One lab study has shown acellular dermal matrix leads to reduced chance of inflammatory response. ²
Allograft	Reduced risk of rejection as compared with xenograft ^{3,4}
Infiltrated by host tissue	For effective graft procedures
High suture pull-out strength	Enhances tissue reinforcement
Provided sterile	Proprietary process, provides the one of a few acellular dermal matrix products that is irradiated under validated sterilization process. Using sterile graft further reduces the risk of disease donor transmission. ⁵
Convenient delivery sizes	Multiple sizes to address surgeon's needs
No special handling or storage requirements	Does not need to be refrigerated
Easily reconstituted in the O.R.	Simply hydrate in normal saline
Consistent material	Consistent thickness throughout entire implant

Meets all FDA, AATB and state regulatory requirements for testing and donor screening

Ultimate Tensile Strength for Various Acellularized Dermis⁷




Tensile Strength⁶

Tensile strength is defined as the pulling force required to break a material standardized to its cross-sectional area.

- 19.2 MPa
- Exceeded tensile strength of competitor ACD graft

ACD Suture Pull-out Strength vs. Suture Break Strength⁷



Suture Pull-out Strength⁶

Suture pull-out strength is defined as the force required to separate the suture from the graft material.

- Suture failed before graft (Excel 0.0 Green Braided Suture)
- 166.1 Newtons pull-out with stainless steel wire

Ordering Information

DermaSpan Acellular Dermal Matrix

Catalog #	Size	Thickness
48-0700404	4 cm – 4 cm	0.5 mm – 0.9 mm
48-0700408	4 cm – 8 cm	0.5 mm – 0.9 mm
48-1100407	4 cm – 7 cm	0.8 mm – 1.4 mm
48-1100510	5 cm – 10 cm	0.8 mm – 1.4 mm
48-1100505	5 cm – 5 cm	0.8 mm – 1.4 mm
48-0900307	3 cm – 7 cm	0.9 mm – 1.99 mm
48-0900407	4 cm – 7 cm	0.9 mm – 1.99 mm
48-0900412	4 cm – 12 cm	0.9 mm – 1.99 mm
48-0900416	4 cm – 16 cm	0.9 mm – 1.99 mm
48-0900510	5 cm – 10 cm	0.9 mm – 1.99 mm
48-0900612	6 cm – 12 cm	0.9 mm – 1.99 mm
48-0900616	6 cm – 16 cm	0.9 mm – 1.99 mm
48-0900812	8 cm – 12 cm	0.9 mm – 1.99 mm
48-0900816	8 cm – 16 cm	0.9 mm – 1.99 mm
48-0901212	12 cm – 12 cm	0.9 mm – 1.99 mm
48-0901620	16 cm – 20 cm	0.9 mm – 1.99 mm

Catalog #	Size	Thickness
48-200.0307	3 cm – 7 cm	2.0 mm – 3.5 mm
48-2000407	4 cm – 7 cm	2.0 mm – 3.5 mm
48-2000412	4 cm – 12 cm	2.0 mm – 3.5 mm
48-2000416	4 cm – 16 cm	2.0 mm – 3.5 mm
48-2000510	5 cm – 10 cm	2.0 mm – 3.5 mm
48-2000612	6 cm – 12 cm	2.0 mm – 3.5 mm
48-2000616	6 cm – 16 cm	2.0 mm – 3.5 mm
48-2000812	8 cm – 12 cm	2.0 mm – 3.5 mm
48-2000816	8 cm – 16 cm	2.0 mm – 3.5 mm
48-2001212	12 cm – 12 cm	2.0 mm – 3.5 mm
48-2001620	16 cm – 20 cm	2.0 mm – 3.5 mm

The DermaSpan Acellular Dermal Matrix is available in multiple sizes and thicknesses. Selection for the appropriate product size is the responsibility of the surgeon based on the individual patient needs. Graft thickness and strength should be considered based on application.

All content herein is protected by copyright, trademarks and other intellectual property rights, as applicable, owned by or licensed to Zimmer Biomet or its affiliates unless otherwise indicated, and must not be redistributed, duplicated or disclosed, in whole or in part, without the express written consent of Zimmer Biomet.

This material is intended for health care professionals. Distribution to any other recipient is prohibited.

For product information, including indications, contraindications, warnings, precautions, potential adverse effects and patient counseling information, see the package insert or contact your local representative; visit www.zimmerbiomet.com for additional product information.

Third party product names and trademarks used in this document are the property of their respective owners.

©2019 Zimmer Biomet

References

1. Tissue Banks International. Histological investigations of recellularization, revascularization, adhesions and other factors in three animal models of Tissue Banks Internationals sterile human acellular dermal allograft. April 27, 2010. Animal studies are not necessarily indicative of clinical performance.
2. Richters, C. D., A. Pirayesh, H. Hoeksema, E. W. A. Kamperdijk, R. W. Kreis, R. P. Dutrieux, S. Monstrey, and M. J. Hoekstra. "Development of a Dermal Matrix from Glycerol Preserved Allogeneic Skin." *Cell and Tissue Banking* 9.4 (2008): 309-15. Print.
3. Jacobsen, Garth, and David Easter. "Allograft vs. Xenograft Practical Considerations for Biologic Scaffolds." *BellaDerm*. MTF. Web. 07 Feb. 2011. <<http://www.belladerm.org/documents/AVX%20%20CME%20Monograph.pdf>>.
4. Michael, Trice E. "Xenograft Risks: What You and Your Patients Need to Know." *American Academy of Orthopaedic Surgeons—AAOS*. June 2009. Web. 07 Feb. 2011. <<http://www.aaos.org/news/aaosnow/jun09/research3.asp>>.
5. McNickle, A.G., Wang, V.M., Shewman, E.F., Cole, B.J., and Williams, J.M.: "Performance of a Sterile Meniscal Allograft in an Ovine Model." 465(7):1868–1876, *Clinical Orthopaedics and Related Research*, July 2009.
6. Tissue Banks International. Mechanical testing of Tissue Banks International's acellular dermis (ACD) allograft. May 18, 2010.
7. As reported by Dermatrix™ Acellular Dermis— Informational Brochure. Synthes and Musculoskeletal Transplant Foundation Allopatch HD™ Acellular Human Dermis – Informational Brochure. Musculoskeletal Transplant Foundation. *Bench test results are not necessarily indicative of clinical performance.



Distributed By:
 Biomet Biologics
 56 East Bell Drive
 P.O. Box 587
 Warsaw, IN 46581
 USA